Neumora Therapeutics Inc.... (NMRA)
undefined
undefined%
At close: undefined
10.32
0.29%
After-hours Dec 13, 2024, 04:39 PM EST

Company Description

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases.

The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.

It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders.

In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease.

The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021.

Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.

Neumora Therapeutics Inc. Common Stock
Neumora Therapeutics Inc. Common Stock logo
Country United States
IPO Date Sep 15, 2023
Industry Biotechnology
Sector Healthcare
Employees 124
CEO Henry O. Gosebruch

Contact Details

Address:
490 Arsenal Way
Watertown,
United States
Website https://www.neumoratx.com

Stock Details

Ticker Symbol NMRA
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001885522
CUSIP Number 640979100
ISIN Number US6409791000
Employer ID 84-4367680
SIC Code 2836

Key Executives

Name Position
Henry O. Gosebruch President, Chief Executive Officer & Director
Carol Suh Co-Founder & Chief Operating Officer
Jason G. Duncan J.D. Chief Legal Officer
Paul L. Berns Co-Founder & Executive Chairman
Robert Lenz M.D., Ph.D. Head of Research & Development

Latest SEC Filings

Date Type Title
Nov 22, 2024 SC 13D/A [Amend] Filing
Nov 12, 2024 SC 13G Statement of acquisition of beneficial ownership b...
Nov 12, 2024 10-Q Quarterly Report
Nov 12, 2024 8-K Current Report
Oct 18, 2024 4 Filing
Oct 11, 2024 4 Filing
Oct 01, 2024 S-3ASR Automatic shelf registration statement of securiti...
Sep 19, 2024 4 Filing
Sep 16, 2024 4 Filing
Sep 13, 2024 4 Filing